Metformin-associated lactic acidosis;Acidose lactique et metformine

Annales Francaises d'Anesthesie et de Reanimation

Volumn 25, Issue 10, 2006, Pages 1046-1052

  Orban, J C ^a   Ghaddab, A ^b   Chatti, O ^c   Ichai, C ^a  

^a University Hospital of Nice University of Nice Sophia Antipolis   (France)

^b MONGI SLIM HOSPITAL   (Tunisia)

^c MILITARY HOSPITAL OF TUNIS   (Tunisia)

Author keywords

Biguanide; Diabetes mellitus; Lactic acidosis; Metformin

Indexed keywords

ANTIDIABETIC AGENT; BIGUANIDE; INSULIN; METFORMIN; PHENFORMIN; BIGUANIDE DERIVATIVE;

ABDOMINAL PAIN; CARDIOVASCULAR DISEASE; DATA EXTRACTION; DATA SYNTHESIS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; FRANCE; GASTROINTESTINAL SYMPTOM; GLUCONEOGENESIS; GLYCEMIC CONTROL; HUMAN; INSULIN SENSITIVITY; LACTIC ACIDOSIS; MEDLINE; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT SAFETY; PRESCRIPTION; PROGNOSIS; RENAL REPLACEMENT THERAPY; SHORT SURVEY; VOMITING; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; REVIEW;

ACIDOSIS, LACTIC; BIGUANIDES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 33751037600     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2006.05.009     Document Type: Short Survey

References (76)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
2. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25 (2002) 224-228
3. Scarpello J.H.B. Improving survival with metformin: the evidence base today. Diabetes Metab. 29 (2003) 6836-6843
4. Kirpichnikov D., McFarlane S.I., and Sowers J.R. Metformin: an update. Ann. Intern. Med. 137 (2002) 25-33
5. Howlett H.C.S., and Bailey C.J. A risk-benefit assessment of metformin therapy in type 2 diabetes mellitus. Drug Saf. 6 (1999) 489-503
6. Garber A.J., Duncan T.G., and Goodman A.M. Efficacy of metformin in type II diabetes: results of a double-blind placebo controlled, dose response trial. Am. J. Med. 102 (1997) 491-497
7. Misbin R.I., Green L., Stadel B.V., Gueriguian J.L., Gubbi A., and Fleming G.A. Lactic acidosis in patients with diabetes treated with metformin. N. Engl. J. Med. 338 (1998) 265-266
8. Salpeter S.R., Greyber E., Pasternak G.A., and Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch. Intern. Med. 163 (2003) 2594-2602
9. Lalau J.D., and Race J.M. Lactic acidosis in metformin therapy. Drugs 58 (1999) 55-82
10. Lalau J.D., and Race J.M. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 20 (1999) 377-384
11. Chang C.T., Chen Y.C., Fang J.T., and Huang C.C. Metformin-associated lactic acidosis: case reports and literature review. J. Nephrol. 15 (2002) 398-402
12. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 131 (1999) 281-303
13. Bailey C.J., and Turner R.C. Metformin. N. Engl. J. Med. 334 (1996) 574-579
14. Scheen A.J. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 30 (1996) 359-371
15. Hundal R.S., and Inzucchi S.E. Metformin. New understandings, new users. Drugs 63 (2003) 1879-1894
16. Sambol N.C., Chiang J., O'Conner M., Liu C.Y., Lin E.T., Goodman A.M., et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J. Clin. Pharmacol. 36 (1996) 1012-1021
17. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287 (2002) 360-372
18. Melin B., Cherqui G., Blivet M.J., Caron M., Lascols O., Capeau J., et al. Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism 39 (1990) 1089-1095
19. Bailey C.J., Wilcock C., and Day C. Effect of metformin on glucose metabolism in the splanchnic bed. Br. J. Pharmacol. 105 (1992) 1009-1013
20. Matthaei S., Reibold J.P., Hamann A., Benecke H., Haring H.U., Greten H., et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 133 (1993) 304-311
21. Stith B.J., Goalstone M.L., Espinoza R., Mossel C., Roberts D., and Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinology 137 (1996) 2990-2999
22. Stumvoll M., Nurjhan N., Perriello G., Dailey G., and Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333 (1995) 550-554
23. Owen M.R., Doran E., and Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348 (2000) 607-614
24. El-Mir M.Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275 (2000) 223-228
25. Rossetti L., DeFronzo R.A., Gherzi R., Stein P., Andraghetti G., Falzetti G., et al. Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations. Metabolism 39 (1990) 425-435
26. Cigolini M., Bosello O., Zancanaro C., Orlandi P.G., Fezzi O., and Smith U. Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. Diabete Metab. 10 (1984) 311-315
27. Riccio A., Del Prato S., Vigili de Kreutzenberg S., and Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. Diabetes Metab. 17 (1991) 180-184
28. DeFronzo R.A., and Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N. Engl. J. Med. 333 (1995) 541-549
29. Grant P.J., Stickland M.H., Booth N.A., and Prentice C.R. Metformin causes a reduction in basal and postvenous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet. Med. 8 (1991) 361-365
30. Nagi D.K., and Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 16 (1993) 621-629
31. Charles M.A., Morange P., Eschwege E., Andre P., Vague P., and Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 21 (1998) 1967-1972
32. Selby J.V., Ettinger B., Swain B.E., and Brown J.B. First 20 month's experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 22 (1999) 38-44
33. Emslie-Smith A.M., Boyle D.I., Evans J.M., Sullivan F., and Morris A.D. DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with Type 2 diabetes -a population-based study of adherence to prescribing guidelines. Diabet. Med. 18 (2001) 483-488
34. Chan N.N., Fauvel N.J., and Feher M.D. Non-steroidal anti-inflammatory drugs and metformin: a cause for concern?. Lancet 352 (1998) 201
35. Kruse J.A. Metformin-associated lactic acidosis. J. Emerg. Med. 20 (2001) 267-272
36. Brown J.B., Pedula K., Barzilay J., Herson M.K., and Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 21 (1998) 1659-1663
37. Cusi K., Consoli A., and DeFronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81 (1996) 4059-4067
38. Cryer D.R., Nicholas S.P., Henry D.H., Mills D.J., and Stadel B.V. Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 28 (2005) 539-543
39. Al Jebawi A.E., Lassman M.N., and Abourizk N.N. Lactic acidosis with therapeutic metformin blood level in a low-risk diabetic patient. Diabetes Care 21 (1998) 1364-1367
40. Siang M.R., Wysowski D.K., and Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 22 (1999) 925-927
41. Lalau J.D., Laevix C., Couragon P., deCagney B., Rigaud J.P., Bleichner G., et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18 (1995) 779-784
42. Pertek J.P., Vidal S., Mariot J., Galy-Floc'h M., and Azoulay E. Acidose lactique toxique à la metformine provoquée par une insuffisance rénale aiguë. Ann. Fr. Anesth. Reanim. 22 (2003) 457-460
43. Orban J.C., Giunti C., Levraut J., Grimaud D., and Ichai C. L'acidose lactique reste une complication grave du traitement par metformine. Ann. Fr. Anesth. Reanim. 22 (2003) 461-465
44. Teale K.F., Devine A., Stewart H., and Harper N.J. The management of metformin overdose. Anaesthesia 53 (1998) 698-701
45. Nisse P., Mathieu-Nolf M., Deveaux M., Forceville X., and Combes A. A fatal case of metformin poisoning. J. Toxicol. Clin. Toxicol. 41 (2003) 1035-1036
46. Argaud D., Roth H., Wiernsperger N., and Leverve X.M. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur. J. Biochem. 213 (1993) 1341-1348
47. Cohen R.D., and Woods H.F. Lactic acidosis revisited. Diabetes 32 (1983) 181-191
48. Stacpoole P.W. Lactic acidosis. Endocrinol. Metab. Clin. North Am. 22 (1993) 221-245
49. Arieff A.I. Pathogenesis of lactic acidosis. Diab. Metab. Rev. 5 (1989) 637-649
50. Machet G., and Coudray J.M. Acidose lactique et metformine impliquée : pourquoi mieux informer sur les facteurs de risque?. Therapie 55 (2000) 283-294
51. Setter S.M., Iltz J.L., Thams J., and Campbell R.C. Metformin hydrochlorid in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin. Ther. 25 (2003) 2991-3026
52. Robert F., Fundi S., Hary L., Lacroix C., Andregali M., and Lalau J.D. Kinetic of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab. 29 (2003) 279-283
53. Lalau J.D., and Lacroix C. Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes Obes. Metab. 5 (2003) 93-98
54. Stades A.M., Heikens J.T., Erkelens D.W., Holleman F., and Hoekstra J.B. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J. Intern. Med. 255 (2004) 179-187
55. Stacpoole P.W. Metformin and lactic acidosis. Guilt by association?. Diabetes Care 21 (1998) 1586-1587
56. Montanari G., Bondioli A., Rizzato G., Puttini M., Tremoli E., Mussoni L., et al. Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol. Res. 25 (1992) 63-73
57. Bonnefont-Rousselot D., Raji B., Walrand S., Gardes-Albert M., Jore D., Legrand A., et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 52 (2003) 586-589
58. Pavlovic D., Kocic R., Kocic G., Jevtovic T., Radenkovic S., Mikic D., et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes. Metab. 2 (2000) 251-256
59. Vornov J.J., Thomas A.G., and Jo D. Protective effects of extracellular acidosis and blockade of sodium/hydrogen ion exchange during recovery from metabolic inhibition in neuronal tissue culture. J. Neurochem. 67 (1996) 2379-2389
60. Xu L., Glassford A.J., Giaccia A.J., and Giffard R.G. Acidosis reduces neuronal apoptosis. Neuroreport 9 (1998) 875-879
61. Mathieu D., Nevière R., Billard V., Fleyfel M., and Wattel F. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit. Care Med. 19 (1991) 1352-1356
62. Cooper D.J., Walley K.R., Wiggs B.R., and Russel J.A. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis: a prospective, controlled clinical study. Ann. Intern. Med. 112 (1990) 492-498
63. Stacpoole P.W., Wright E.C., Baumgartner T.G., Bersin R.M., Buchalter S., Curry S.H., et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N. Engl. J. Med. 327 (1992) 1564-1569
64. e Conférence de consensus en réanimation et médecine d'urgence. Correction de l'acidose métabolique en réanimation. Réan. Urg. 8 (1999) 426-432
65. Panzer U., Kluge S., Kreymann G., and Wolf G. Combination of intermittent haemodialysis and high-volume continuous haemofiltration for the treatment of severe metformin-induced lactic acidosis. Nephrol. Dial. Transplant. 19 (2004) 2157-2158 [letter]
66. Mariano F., Benzi L., Cecchetti P., Rosatello A., Merante D., Goix F., et al. Efficacy of continuous veno-venous haemofiltration (CVVH) in the treatment of severe phenformin-induced lactic acidosis. Nephrol. Dial. Transplant. 13 (1998) 1012-1015
67. Barrueto F., Meggs W.J., and Barchman M.J. Clearance of metformin by hemofiltration in overdose. J. Toxicol. Clin. Toxicol. 40 (2002) 177-180
68. Lacher M., Hermanns-Clausen M., Haeffner K., Brandis M., and Pohl M. Severe metformin intoxication with lactic acidosis in an adolescent. Eur. J. Pediatr. 164 (2005) 362-365
69. Levraut J., Ciebiera J.P., Jambou P., Ichai C., Labib Y., and Grimaud D. Effect of continuous venovenous hemofiltration with dialysis on lactate clearance in critically ill patients. Crit. Care Med. 25 (1997) 58-62
70. Ichai C., Levraut J., Samat-Long C., and Grimaud D. Acidose lactique et biguanide : coïncidence ou négligence des règles de prescription?. Ann. Fr. Anesth. Reanim. 22 (2003) 399-401
71. Lalau J.D., Andrejak M., Moriniere P., Coevoet B., Debussche X., Westeel P.F., et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int. J. Clin. Pharmacol. Ther. Toxicol. 27 (1989) 285-288
72. Holstein A., Nahrwold D., Hinze S., and Egberts E.H. Contra-indications to metformin therapy are largely disregarded. Diabet. Med. 16 (1999) 692-696
73. Jones G.C., Macklin J.P., and Alexander W.D. Contraindications to the use of metformin. BMJ 326 (2003) 4-5
74. McCormack J., Johns K., and Tildesley H. Metformin's contraindications should be contraindicated. CMAJ 173 (2005) 502-504
75. Rachmani R., Slavachevski I., Levy Z., Zadok B., Kedar Y., and Ravid M. Metformin in patients with type 2 diabetes: reconsideration of traditional contra-indications. Eur. J. Intern. Med. 13 (2002) 428-433
76. Franzetti I., Paolo D., Marco G., Emanuela M., Elisabetta Z., and Renato U. Possible synergistic effect of metformin and enalapril on the development of hyperkaliemic lactic acidosis. Diabetes Res. Clin. Pract. 38 (1997) 173-176